THE HEART OF THE MATTER
Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The company is focused on the development of minimally-invasive treatments for two of the most vexing challenges in cardiology today; refractory angina and mitral regurgitation. We believe there is tremendous potential in addressing these hard-to-treat conditions.
Neovasc is a publicly-traded company on both the NASDAQ and Toronto stock exchanges.
NVCN
NASDAQ
TORONTO (TSX)
NEOVASC Q1 Earnings Call
Thursday, May 12, 2022 at 4:30 p.m. ET
Webcast: register here
Conference call by dialing (877) 407-9208 or
(201) 493-6784 (International)
and reference Conference ID 13729200